Alcon Eye Laser Hyperopia With Astigmatism Approval Provides Edge, For Now
This article was originally published in The Gray Sheet
Executive Summary
FDA approval of Alcon Summit Autonomous' LADARVision device for laser-assisted in situ keratomileusis (Lasik) treatment of hyperopia with or without astigmatism, and for mixed astigmatism, gives the firm an exclusive market niche, if only temporarily.
You may also be interested in...
Visx Gains Panel Nod For Star S2 Hyperopia PRK Indication
Labeling for Visx' Star S2 excimer laser for treatment of hyperopia (far-sightedness) with astigmatism using photorefractive keratectomy (PRK) should reflect the lack of data relating to refractive stability in the company's premarket approval application supplement, FDA's Ophthalmic Device Panel recommended at a May 11 meeting in Gaithersburg, Maryland.
LADARVision Gets Panel Nod For LASIK Hyperopia Correction With Conditions
Laser-assisted in situ keratomileusis (LASIK) labeling for Autonomous Technologies Corp.' s LADARVision ophthalmic excimer laser system should highlight declining predictability of outcome in patients with a pre-operative manifest refractive spherical equivalance (MRSE) or uncorrected visual acuity (UCVA) greater than +/-4 diopters.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.